Humana (NYSE:HUM) Releases FY 2025 Earnings Guidance

by · The Cerbat Gem

Humana (NYSE:HUM – Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 17.000-17.000 for the period, compared to the consensus estimate of 17.050. The company issued revenue guidance of -.

Humana Stock Performance

HUM opened at $251.46 on Friday. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market cap of $30.24 billion, a price-to-earnings ratio of 19.30, a PEG ratio of 1.71 and a beta of 0.42. Humana has a 52-week low of $206.87 and a 52-week high of $315.35. The firm’s fifty day simple moving average is $278.04 and its two-hundred day simple moving average is $258.89.

Humana (NYSE:HUM – Get Free Report) last released its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.29. The business had revenue of $32.65 billion during the quarter, compared to analysts’ expectations of $31.99 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.16 earnings per share. Equities analysts anticipate that Humana will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, December 26th. Humana’s dividend payout ratio (DPR) is 27.17%.

Analysts Set New Price Targets

Several analysts recently commented on the company. Robert W. Baird dropped their price target on Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Bank of America upped their target price on shares of Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a report on Friday, October 10th. Guggenheim reiterated a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Piper Sandler lowered their price target on shares of Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a research report on Thursday, July 31st. Finally, Wells Fargo & Company increased their price objective on shares of Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a report on Tuesday, October 7th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $299.22.

View Our Latest Stock Report on HUM

Hedge Funds Weigh In On Humana

Several large investors have recently made changes to their positions in HUM. 8 Knots Management LLC increased its holdings in Humana by 671.0% in the 2nd quarter. 8 Knots Management LLC now owns 441,623 shares of the insurance provider’s stock valued at $107,968,000 after purchasing an additional 384,345 shares during the last quarter. Man Group plc grew its stake in shares of Humana by 179.5% in the second quarter. Man Group plc now owns 580,943 shares of the insurance provider’s stock valued at $142,029,000 after buying an additional 373,071 shares in the last quarter. Holocene Advisors LP purchased a new stake in shares of Humana in the 2nd quarter valued at $64,595,000. Teewinot Capital Advisers L.L.C. acquired a new position in Humana during the 2nd quarter worth about $52,058,000. Finally, Canada Pension Plan Investment Board boosted its holdings in Humana by 63.3% during the 2nd quarter. Canada Pension Plan Investment Board now owns 436,047 shares of the insurance provider’s stock valued at $106,605,000 after acquiring an additional 169,068 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles